Clinical trials
Neovascular Age-Related Macular Degeneration (nAMD) clinical trials
Below are recruiting neovascular age-related macular degeneration (namd) clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Mesa, ArizonaAges 50 years+ - NCT05672121RecruitingPhase 1/Phase 2
Gene therapy safety study for neovascular macular degeneration
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
BeijingAges 50–85 - NCT05803785RecruitingPhase 1
Safety study of an injection for wet macular degeneration
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Sydney, New South WalesAges 50 years+ - NCT06346600Recruiting
Long-term follow-up for SKG0106 in wet AMD
This study follows people who already received the SKG0106 injection in a previous trial for wet age-related macular degeneration (nAMD). It checks how they are doing over a longer period.
Boston, MassachusettsAges 50 years+ - NCT06458595RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration (nAMD)
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
TianjinAges 50–85 - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Scottsdale, ArizonaAges 50 years+ - NCT07235527Recruiting
Aflibercept biosimilar for wet age-related macular degeneration
This study tests a biosimilar version of aflibercept (a drug that blocks abnormal blood vessel growth) in people with wet age-related macular degeneration. It aims to see how well the treatment works in real life.
Istanbul, şişliAges 45–90 - NCT07249216Recruiting
Eye fluid study for wet AMD treatment response
This study looks at eye fluid from people with untreated wet AMD to find out why some don't respond well to standard injections. The goal is to improve future treatments.
SingaporeAges 50 years+ - NCT07308639Recruiting
Eye disease health data study in Germany
This study looks at health records in Germany to understand how many people have certain eye conditions like age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. It also tests new ways to use this information for research.
LeverkusenAges 18 years+ - NCT07660640Enrolling by invitation
Long-term follow-up for VOY-101 eye injection study
This study follows up with people who already received the VOY-101 injection for a type of age-related vision loss (non-neovascular age-related macular degeneration) in an earlier study. It checks how they are doing over a longer period of time.
Boston, MassachusettsAges 50 years+ - NCT03999801Enrolling by invitationPhase 2
Long-term follow-up for a subretinal eye treatment
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
Phoenix, ArizonaAges 50 years+
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neovascular age-related macular degeneration (namd)?
- Yes. Clin2 currently lists 35 recruiting neovascular age-related macular degeneration (namd) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neovascular age-related macular degeneration (namd) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neovascular age-related macular degeneration (namd) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-Related Macular Degeneration
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.